VASARI 胶质瘤特征十年:其影响与性能的系统综述与荟萃分析
该系统综述与荟萃分析纳入35项研究共3304例患者,评估VASARI胶质瘤特征对总生存、无进展生存及IDH突变的预测性能;多灶性、室管膜侵犯和强化肿瘤跨中线预测总生存的合并风险比最高,联合VASARI特征的IDH预测模型合并AUC为0.82(95%CI 0.76-0.88,I²=100%),VASARI联合临床和/或影像组学特征的模型在所有相关研究中优于单一数据类型模型。
要点
- 强化肿瘤跨中线预测总生存的合并HR=2.08(95%CI 1.35-3.18,I²=52%)。
- 多灶性预测总生存的合并HR=1.80(95%CI 1.21-2.67,I²=53%)。
- 联合VASARI特征的IDH突变预测模型合并AUC=0.82(95%CI 0.76-0.88,I²=100%)。
核心结论
- 部分VASARI特征在预测总生存和IDH突变状态方面表现良好,但联合模型优于单一特征;需要更多异质性较低的研究以提高证据级别。
研究设计与样本
- 系统综述与荟萃分析,检索MEDLINE、Web of Science、EMBASE和Cochrane Library至2023年9月26日,纳入35项原始研究共3304例胶质瘤患者,采用改良QUADAS-2工具评估偏倚风险,荟萃分析采用随机效应模型。
诊断标准与关键数值
- 预测总生存合并风险比最高的单一VASARI特征:多灶性HR=1.80(95%CI 1.21-2.67,I²=53%)、室管膜侵犯HR=1.73(95%CI 1.45-2.05,I²=0%)、强化肿瘤跨中线HR=2.08(95%CI 1.35-3.18,I²=52%)。
- 联合VASARI特征的IDH突变预测模型合并AUC=0.82(95%CI 0.76-0.88),异质性I²=100%。
- 7项研究检查了无进展生存,其中4项研究(胶质母细胞瘤2项、2/3级胶质瘤1项、3级胶质瘤1项)发现无进展生存与单一VASARI特征之间存在显著关联。
临床应用与阅片要点
- VASARI特征可用于胶质瘤报告的结构化术语,其中多灶性、室管膜侵犯和强化肿瘤跨中线对总生存预测价值较高。
- VASARI联合临床和/或影像组学特征的模型在所有相关研究(n=17)中优于单一数据类型模型,提示联合模型可能提升预测性能。
局限性
- 研究设计异质性大,且常样本量小。
- 多项研究使用The Cancer Imaging Archive数据库,队列可能存在重叠。
- IDH突变的荟萃分析因研究异质性高而受限。
- 需要更多异质性较低的研究以提高证据级别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Visually Accessible Rembrandt (Repository for Molecular Brain Neoplasia Data) Images (VASARI) features, a vocabulary to establish reproducible terminology for glioma reporting, have been applied for a decade, but a systematic performance evaluation is lacking.
PURPOSE: Our aim was to conduct a systematic review and meta-analysis of the performance of the VASARI features set for glioma assessment.
DATA SOURCES: MEDLINE, Web of Science, EMBASE, and the Cochrane Library were systematically searched until September 26, 2023.
STUDY SELECTION: Original articles predicting diagnosis, progression, and survival in patients with glioma were included.
DATA ANALYSIS: The modified Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was applied to evaluate the risk-of-bias. The meta-analysis used a random effects model and forest plot visualizations, if ≥5 comparable studies with a low or medium risk of bias were provided.
DATA SYNTHESIS: Thirty-five studies (3304 patients) were included. Risk-of-bias scores were medium (n = 33) and low (n = 2). Recurring objectives were overall survival (n = 18) and isocitrate dehydrogenase mutation (IDH; n = 12) prediction. Progression-free survival was examined in 7 studies. In 4 studies (glioblastoma n = 2, grade 2/3 glioma n = 1, grade 3 glioma n = 1), a significant association was found between progression-free survival and single VASARI features. The single features predicting overall survival with the highest pooled hazard ratios were multifocality (hazard ratio = 1.80; 95%-CI, 1.21-2.67; I2 = 53%), ependymal invasion (hazard ratio = 1.73; 95% CI, 1.45-2.05; I2 = 0%), and enhancing tumor crossing the midline (hazard ratio = 2.08; 95% CI, 1.35-3.18; I2 = 52%). IDH mutation-predicting models combining VASARI features rendered a pooled area under the receiver operating characteristic curve of 0.82 (95% CI, 0.76-0.88) at considerable heterogeneity (I2 = 100%). Combined input models using VASARI plus clinical and/or radiomics features outperformed single data-type models in all relevant studies (n = 17).
LIMITATIONS: Studies were heterogeneously designed and often with a small sample size. Several studies used The Cancer Imaging Archive database, with likely overlapping cohorts. The meta-analysis for IDH was limited due to a high study heterogeneity.
CONCLUSIONS: Some VASARI features perform well in predicting overall survival and IDH mutation status, but combined models outperform single features. More studies with less heterogeneity are needed to increase the evidence level.
引用
- Azizova A, Prysiazhniuk Y, Wamelink IJHG, et al. Ten Years of VASARI Glioma Features: Systematic Review and Meta-Analysis of Their Impact and Performance. AJNR Am J Neuroradiol. 2024. PMID: 38937115. doi:10.3174/ajnr.A8274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。